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Background:  Attenuated  Listeria  monocytogenes  vaccine  strains  have  been  administered  intravenously  (Le
et al.  [1], Maciag  et al. [2]) and  orally  (Angelakopoulos  et  al.  [3], Johnson  et al.  [4]) to  humans.  Here,  one
was  given  transcutaneously  with  cholera  toxin  adjuvant.
Methods:  Eight  healthy  volunteers  were  studied  (5 active,  3 placebo).  Safety  was  assessed  by  physical
exam  and labs.  Systemic  immunological  responses  were  measured  by ELISA  and  IFN-gamma  ELISpot.eywords:
isteria monocytogenes
ranscutaneous
accination
LISpot
ttenuated vector
linical trial
Results:  4/5  active  volunteers  had  cellular  responses  to  listerial  antigens.  5/5 active  volunteers  showed
humoral  responses  to cholera  toxin.
Conclusions:  An  attenuated  L.  monocytogenes  vector  was safely  administered  transcutaneously.  Topical
administration  appeared  at least  as  immunogenic  as  previously  studied  oral  delivery.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. . Introduction
The skin contains a complete complement of the body’s immune
ells. An adult may  have as many as 20 billion T cells of various sub-
ypes in the skin, exceeding the number in circulation (reviewed in
5]). Dermal dendritic cells capture antigens and deliver them to
he skin-draining lymph nodes and activate naïve or central mem-
ry T cells stimulating both local and systemic immune responses
5].
Intradermal injections can be vaccine-sparing and effective
6]. Intradermal delivery can be done using traditional needles,
icroneedles, air pressure insufﬂation, iontophoresis, scariﬁca-
ion, or by simple absorption. The microbial enterotoxins cholera
Abbreviations: CBC, complete blood count; CEF, CMV, EBV, and Inﬂuenza virus;
FU, colony forming units; GMP, good manufacturing processes; IFN, interferon;
LO,  listeriolysin; LT, E. coli heat labile toxin; PBMC, peripheral blood mononuclear
ells; PHA, phytohemagglutinin; SFC, spot-forming cells.
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Open access under CC BY-NC-ND toxin and Escherichia coli heat labile toxin and mutants thereof
have been shown to be mucosal and cutaneous immunogens
and potent adjuvants. Transcutaneous administration of LT has
enhanced immune responses to a co-administered bacterial protein
[7], and an injected inﬂuenza vaccine [8].
Live attenuated bacterial vectors based upon enteric pathogens
like Listeria and Salmonella species are relatively easily engi-
neered to express foreign antigens. Unfortunately, they have not
proved highly successful in human studies in stimulating immune
responses to engineered heterologous antigens. Live bacterial vec-
tors administered orally are plagued by several (at least theoretical)
concerns: inadequate attenuation, reversion, recombination, shed-
ding, and the potential for transmission. We  previously evaluated
a highly attenuated Listeria monocytogenes organism expressing
an inﬂuenza A nucleoprotein antigen by the oral route in sin-
gle escalating oral doses in volunteers, and found this organism
safe, transiently shed, but poorly immunogenic and probably over-
attenuated for oral delivery [4].
Despite this apparent failure, we hypothesized that this would
be an ideal, highly attenuated organism to test transcutaneous
application of a live attenuated enteric vector. In mice L. mono-
cytogenes stimulates potent CD4 and CD8T cell responses and
effectively delivers both viral and tumor antigens (reviewed in [9]).
Besides vertical transmission in utero, L. monocytogenes is not trans-
mitted person-to-person. Unlike oral delivery, cutaneous delivery
(though not presentation or antigen processing) can be rapidly
stopped by topical disinfection, and minimizes concerns related
license. 
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o shedding. We  included a native commercially available cholera
oxin adjuvant, in an attempt to maximize immune responses. The
roject was proposed as a novel physiological study of a bacterial
ector delivered transcutaneously, and not as development of a new
nﬂuenza vaccine.
We show that cellular immune responses to complex listerial
ntigens can be engendered by the transcutaneous route. Though
ot compared “head-to-head” these results may  be superior to
hose engendered by delivery of a single large dose orally.
. Materials and methods
.1. Bacterial strain
L. monocytogenes strain BMB72 expressing a secreted inﬂuenza
 nucleoprotein antigen was derived from L. monocytogenes strain
0403S as described [4].
.2. Human subjects
The study was reviewed and approved by the Partners IRB, the
arvard Institutional Biosafety Committee, the FDA (IND # 13937)
nd registered at CT.gov (NCT01311817). Healthy adults who were
8–55 years old and provided written informed consent under-
ent a complete medical screening by history, physical exam and
aboratory evaluation as described [4]. Subjects were not screened
or previous infection with L. monocytogenes or inﬂuenza and were
aid per IRB norms. There is no clinically validated serological test
or prior or active infection with L. monocytogenes.
.3. Inoculum and administration
Research laboratory GMP  methodologies and Standard Operat-
ng Procedures acceptable to the US FDA were used to grow and
haracterize bacterial inocula for clinical use. Bacteria from a mas-
er cell bank were grown aerobically with rotary shaking in 2 L glass
asks in trypticase soy broth (DIFCO, Sparks, MD)  to optical density
.0600 nm, harvested by centrifugation, and re-suspended in normal
aline/20% USP glycerol (15:1 concentration by volume). Bacteria
ere not washed. Individual cryovials were ﬁlled by manual pipet-
ing, frozen at −80 ◦C, and assessed at manufacture and every 3–6
onths thereafter, for purity and stability, using microbial limits
esting and CFU/ml determinations respectively over time. There
ere pre-speciﬁed acceptance criteria for use in humans.
Native, sterile, preservative-free biologically active cholera
oxin (List Biological Laboratories, Inc.) was used. Based
pon spread plate cultures, the thawed inoculum contained
.0 × 1010 CFU/dose and also contained approximately 2× that
umber of dead organisms. Cholera toxin (50 g) was  added to the
acterial inoculum (Lot ELH072910), and a 1 mL  volume pipetted
nto the absorbent pad of a Tegaderm patch (3 M Company)
Fig. 1). Preclinical cutaneous toxicology studies were performed
sing CT and the bacterial strain in animals by both the oral and
utaneous routes.
The deltoid regions were ﬁrst exfoliated with dry ECG prep
ads (Marquette Medical Systems, Jupiter, FL), then with electrode
kin prep pads containing alcohol and silica (Dynarex Company)
o remove excess stratum corneum. Vaccine patches were then
pplied and left in place for up to 24 h (Fig. 1). Each volunteer
eceived two patches: either one active and one placebo (saline),
r two placebos. Two patches were used, to assess reaction to the
atch alone and the volunteer’s assignment of active vs. placebo
atch. Subjects were randomly assigned to active vs. placebo and
he study physician and subjects were blinded to assignments. After
emoval, patch sites were sequentially cleaned with alcohol wipes,1 (2013) 3257– 3261
a surgical scrub sponge with 3% chloroxylenol (Beckton, Dickinson
and Company), and Calstat antiseptic hand rub (Steris).
2.4. Clinical assessments
Subjects were seen as outpatients. Vaccinations were given on
days 0, 21, and 35. Volunteers were examined 24 and 48 h after
removal of patches. Safety labs (CBC, liver function tests) were done
48 h after each vaccine removal and at a ﬁnal visit. Temperature
was monitored at each visit, and by subjects at home. PBMC were
isolated from heparinized blood on days 0, 35, and 42. Serum was
collected weekly starting on day 21 (Supplementary Fig. 1, study
schema; online).
2.5. Interferon- ELISpot studies
IFN- ELISpot studies were performed as described [3,4] using
freshly isolated PBMC on Immobilon P (MAIPS4510; Millipore)
plates containing various peptide pools and complex antigens.
Bulk, freshly isolated mononuclear cells isolated by Ficoll gradi-
ent centrifugation and counted using a slide-based Nexcelcom
automated cell counter were used without further characteriza-
tion. Control wells included PHA and CEF, a commercial standard
peptide pool including 32 CMV, EBV and inﬂuenza virus peptides
8–12 amino acids in length (AnaSpec). Test peptides included 3
inﬂuenza nucleoprotein peptide pools and a single LLO peptide
pool used in our prior oral administration study [4], the latter a gift
of Cerus corporation. Complex antigens included whole sonicated
L. monocytogenes, and a soluble antigen from spent L. monocyto-
genes culture medium. Spots were counted by an automated reader
(Immunospot 3; CTL). ELISpot results are presented as mean val-
ues of duplicate wells per condition as SFC/106 PBMC. A positive
response was  deﬁned as more than 2-fold greater than baseline
spots for that antigen and over 100 SFC/106 PBMC as in our ear-
lier study [4]. Groups were compared using Fisher’s exact test (two
tailed).
2.6. Seroconversion/ELISA
Serum samples were studied by ELISA to quantify immunoglob-
ulin G [10] directed against the complex listerial antigens,
recombinant his-tagged LLO, cholera toxin, and recombinant
inﬂuenza A nucleoprotein over time. Antigens (10 g/mL) were
used to coat Maxisorp 96-well plates (Nalge Nunc International).
Assays were performed as described [4] with goat-anti-human IgG
afﬁnity-puriﬁed peroxidase-labeled antibody and read on a Vmax
kinetic microplate reader (Molecular Devices). Endpoint titers are
reported as the highest dilution at which a serum sample read
at ≥0.15 OD450 nm, an empirically chosen cutoff value. Fourfold
or greater increases in endpoint titer were considered a positive
result. Groups were compared using Fisher’s exact test (two tailed).
3. Results
3.1. Subjects
A total of 22 people were screened by phone, 12 underwent
complete screening, and 8 completed the study (7 men, 1 woman;
all Caucasian).
3.2. Clinical responsesNo volunteer had fever, serious or unexpected problems or clin-
ically signiﬁcant abnormal laboratory ﬁndings. No subject at any
time point studied had liver function tests outside the normal range
(ALT, AST, alkaline phosphatase and Total and Direct Bilirubin).
E.H. Eypper et al. / Vaccine 31 (2013) 3257– 3261 3259
Fig. 1. Tegaderm patch vaccination, cutaneous reaction and ELISpot wells for Volunteer #7. Panels A and B show the Tegaderm patch with pad (arrow) before and after
application. Panels C and D show skin before and 24 h after the second vaccination, the worst rash observed. The lower panel E shows ELISpot wells over time for various
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immediately above), in the absence of any apparent change in controls and listerio
otal WBC  over time are shown in Fig. 2 and show minor excur-
ions outside the normal reference range on the lower end which
s common in young men; differentials were performed and were
linically unremarkable (data not shown). Rashes were graded as
ild, moderate, or severe using pre-deﬁned grading criteria. All
olunteers receiving an active patch were able to correctly identify
he active and placebo patches based upon pruritis and erythema.
olunteers #5 and #7, both active, developed localized moder-
te erythematous papular rashes following the second vaccination
Fig. 1 shows volunteer #7, with the worst rash). The protocol
llowed 2.5% hydrocortisone cream for hypersensitivity reaction
o cholera toxin, but only volunteer #7 used it. Volunteer #7 also
equested delay of the third vaccination by one week because of
he rash.
One volunteer (#4, placebo) spontaneously reported nausea and
rief severe diarrhea without fever approximately 2 weeks after
emoval of the ﬁrst vaccination. He noted that his wife had similartide pool (CEF) listeriolysin peptide pool (LLO), sonicated WT L. monocytogenes (Son
lls with a marked increase over time to listerial antigens compared with baseline
O wells over time.
symptoms; they attributed this to consuming “old” deli meats. He
reported no fever or any other symptoms subsequently. There were
no mishaps or intoxications related to cholera toxin application.
3.3. Humoral immune responses
Baseline end-point dilution IgG titers against recombinant LLO,
complex listerial antigens (as used in ELISpot studies), whole bac-
terial cells (wild type and vaccine organisms) and recombinant
nucleoprotein ranged from 1:160 to 1:10.240. All sera from an indi-
vidual volunteer were evaluated concurrently on the same ELISA
plate, and no individual had a four-fold increase in titer (data not
shown). Modiﬁcations of ELISA conditions designed to decrease
background titers (e.g. modiﬁed secondary antibody dilutions or
blocking solutions) did not alter these ﬁndings. However, 5/5 active
versus 0/3 placebo subjects had a four-fold or greater increase
in endpoint titer cholera toxin (P = 0.018). Subjects had variable
3260 E.H. Eypper et al. / Vaccine 31 (2013) 3257– 3261
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believe these are bona ﬁde given the absence of changes to control
antigens over time, as exempliﬁed in Fig. 1. We acknowledge these
complex bacterial antigens contain inﬂammatory agents and that
the responses likely represent a combination of innate and adaptive
Table 1
Interferon-gamma ELISpot responses to control and listerial antigens. Peripheral
blood mononuclear cells isolated on days 0, 35, and 42/49 were cultured with
5  g/mL antigen. Volunteers 4, 6, and 8 received a control immunization (saline).
Counts represent mean values of IFN-secreting spots per million cells in 2 wells
using CTL Immunospot ELISPOT Reader with Immunospot 5 counting software.
Antigens from left to right: Saline (negative control); PHA (phytohaemagglutinin,
positive control) and CEF (cytomegalovirus, Epstein–Barr virus, inﬂuenza virus pep-
tides, positive control); LLO (listeriolysin-O peptides); SonWT (sonicated wild-type
L.  monocytogenes); Sec Lm (secreted listeria antigen). The asterisks denote a signiﬁ-
cant increase as deﬁned in methods.
Assignment Volunteer Saline CEF LLO Son Lm Sec Lm
Placebo
#4 day 0 5 200 3 8 3
day 42 13 215 5 295* 470*
#6  day 0 0 0 0 83 33
day 42 10 33 58 43 60
#8  day 0 5 15 3 58 390
day 42 10 20 5 68 198
Active
#1  day 0 20 140 10 283 148
day 42 3 108 8 473 128
#2  day 0 13 530 35 175 83
day 42 15 933 35 200 218*
#3  day 0 13 90 10 100 18
day 42 8 30 13 955* 828*ig. 2. Total peripheral blood leukocyte (WBC) counts over time. No consistent tren
losed circle) had known slightly low normal WBC  at baseline and was  included by
aseline titers (1:40 to 1: 5120) that increased an average of 36-
old in the active group but were essentially unchanged in those
eceiving 2 placebo patches (average fold increase 1.3).
.4. IFN- ELISpot results
ELISpot data were analyzed as pre-immune vs. peak value, and
eaks typically occurred on days 35 or 42 (vaccines received on days
, 21, 35). All subjects had marked positive control responses to the
ectin (PHA), and to the CEF control pool at baseline which were
enerally stable over time (Table 1). As expected, all subjects had
etectable baseline spots to at least one of three inﬂuenza nucleo-
rotein peptide test pools. No subject demonstrated an increase
ver time directed against inﬂuenza peptides (data not shown). All
 subjects had baseline responses to both complex listerial anti-
ens, with a mean value of 105 SFC/106 PBMC (range 2 to 282).
FN- secreting cells responsive to one or both of the complex
. monocytogenes antigens increased after vaccination, and were
igniﬁcantly increased in 4/5 active subjects versus 1/3 placebo
Table 1; P = 0.464). Volunteer 7, with the marked rash, had the most
rominent IFN- ELISpot response, as shown pictorially in Fig. 1 and
umerically in Table 1 (∼50-fold increases). Placebo subject #4 had
 marked sustained response to complex listerial antigens at days
5 and 42, following diarrhea in the interval between study days
4 and 21. No signiﬁcant increases were detected in response to
ny of the 3 inﬂuenza nucleoprotein pools or LLO peptides in any
olunteer and responses to the control CEF pool were generally
nchanged over time (Table 1).
. Discussion
Volunteers tolerated the 3 transcutaneous applications well.
utaneous reactions were generally mildly pruritic and erythema-
ous and seemed similar to prior reports of hypersensitivity related
o cutaneous application of LT [7]. There is a syndrome of primary
utaneous listeriosis, a pustular rash that may  lead to disseminatedre noted in total WBC  or differential (not shown) over time. Volunteer 8 (placebo;
l exception request to the ethics committee.
listeriosis, typically in farmers or veterinarians after exposure to
infected abortuses [11]. We  did not observe skin ﬁndings sugges-
tive of cutaneous listeriosis and no subject had fever or systemic
symptoms.
Four of 5 active subjects had apparent increases in cellu-
lar responses to complex listerial antigens after vaccination. We#5  day 0 8 1285 5 128 110
day 42 3 1013 50 433* 260*
#7  day 0 8 628 5 13 38
*day 49 13 645 5 778* 1548*
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[12] Whiting R, Carrington C, Hicks J, Dennis, S, Buchanan R, Brandt M, et al. quan-E.H. Eypper et al. / Va
esponses, from CD4, CD8 and possibly other cell types. The posi-
ive response in one of three control subjects is strikingly related to
 spontaneous report of self-limited gastroenteritis in the subject
nd his wife, after eating “suspect” delicatessen cold cuts, one of
he foods most likely to transmit L. monocytogenes in the USA per
nnum and per serving [12]. It is possible that listerial gastroen-
eritis explains his response, though this represents conjecture. As
e reported these symptoms late, we were not able to perform a
tool culture for Listeria during symptoms, where it might have
een positive. The relative lack of cellular immune responses to
LO peptides is not surprising. Although LLO peptide pools result
n large increases in IFN- response in mice vaccinated parenterally
ith listerial vectors, it appears to engender less of a response in
umans as noted in our prior oral study [4].
The study was originally designed to include a third group of
ubjects who would have randomly received the L. monocytogenes
rganism alone, without cholera toxin. Funding limitations necessi-
ated scaling back to include only placebo and active groups, which
recluded assessing the contribution of CT adjuvant.
As expected, we did not detect cellular or humoral immune
esponses to the vectored inﬂuenza antigen. In our prior study of
his organism, we administered single oral doses of up to 5 × 1010
fter neutralization of stomach acid, and subjects shed the organ-
sm in fecal samples for up to 5 days [4]. There we saw smaller
ncreases in IFN-ELISpot numbers (assays performed with the same
isterial antigens) in about 50% of subjects, and no responses to
nﬂuenza antigens. No subject’s response to listerial antigens was
s prominent as that seen here in Volunteer #7.
Transcutaneous vaccination has practical and perhaps also
mmunological advantages. Resident effector memory T cells in
he skin may  contribute to the production of a robust, long-lasting
esponse [10]. Our data support further exploration of live bacterial
accines and vectors by this route, as both primary vaccines, and
s “boosters.”
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